OSL
ONCOSIL FPO [OSL]
Healthcare · ASX Small Cap
$1.0600 -0.5%
Updated 9 Sep 2026 · Signals refresh every scan
Appeared in 2 consecutive scansFirst seen: 2026-02-25
Get alerts when OSL triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Active Signals
Bullish Signals
- Lagging the Small Ords index — relative strength of 0.86, underperforming its peers
- Trading above the 200-day average — the long-term trend is on your side
- Low cash runway (2 quarters) - dilution risk
- Moderate P/S ratio (6.5x)
- Strong revenue growth (+248%)
- EPS estimates revised downward (-10pts)
- Small-cap ($20-100M)
- Capital raise activity (1 events)
- CANSLIM I: Institutional ownership (39%)
- Sentiment is mixed — no strong consensus either way
- Revenue growing at +248% — the top line is moving in the right direction
- The bigger volume days are the up days — volume-weighted momentum is positive (3.53%/day)
- Beneish M-Score -1.60 > -1.78: likely earnings manipulation
- RBA hiking (-3pts)
Risk Signals
- Trading below both moving averages — the trend is working against this one
- Deeply negative margins (-213%)
- Not enough chatter to gauge sentiment — defaulting to neutral
Expected next for OSL
Window: 26 Oct to 9 Nov
The last 3 moved OSL -3.6% on the day, on average — an observation, not a guide to what happens next.
Each date is labelled with how it is known. A date estimated from past filings is inferred from this company's own filing rhythm — it is not a confirmed date and not a statement about what the company intends to do. See the whole ASX calendar →
Recent Catalysts
NONE Australian Manufacturing Facility Achieves ISO 13485
NONE 100th Patient Treated with OncoSil device in Spain
NONE Proposed issue of securities - OSL
Recent ASX Announcements
| 2026-09-08 | Australian Manufacturing Facility Achieves ISO 13485 PRICE SENSITIVE |
| 2026-09-07 | 100th Patient Treated with OncoSil device in Spain |
| 2026-09-07 | Proposed issue of securities - OSL |
| 2026-09-07 | OSL Secures $5.6 million from Major Institutional Investors PRICE SENSITIVE |
| 2026-09-02 | OncoSil submits US Reimbursement Application (Updated) |
Key Metrics
$32.9M
Market Cap
170K
Avg Volume
1.3x
Vol Ratio
$0.37 — $2.09
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-268.2%
ROE
-213.4%
Profit Margin
CANSLIM Analysis
| Factor | Rating | Detail | |
|---|---|---|---|
| C | Current EPS | fail | EPS Growth: 0% |
| A | Annual Earnings | fail | CAGR: 0% |
| N | New Highs / Catalysts | neutral | |
| S | Supply & Demand | neutral | Float: 82% |
| L | Leader vs Laggard | pass | RS: 47 |
| I | Institutional Sponsorship | pass | Inst: 39% |
| M | Market Direction | neutral | Neutral |
Sector: Healthcare
110 tickers in this sector
View all Healthcare signals →Browse all ASX tickers A–Z →Track OSL and 2,200+ ASX stocks
Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.
No credit card required